Who is Dr. Tracy Beth Høeg and why is her FDA appointment controversial?

Dr. Høeg, a vaccine skeptic, was appointed acting director of the FDA's Center for Drug Evaluation and Research, drawing criticism from agency officials who fear her views may politicize the scientific process.

What are the concerns about the new FDA leadership?

Senior FDA officials are worried that Dr. Høeg's appointment will undermine the agency's reputation for scientific rigor and could deter companies from developing new drugs in the U.S.

Has the FDA's Center for Drug Evaluation and Research seen recent leadership changes?

Yes, Dr. Høeg is the fifth person to lead this office this year, following the recent abrupt resignations of two previous directors amidst internal clashes and reviews.

Home / Health / FDA rocked: Vaccine skeptic takes top drug office role

FDA rocked: Vaccine skeptic takes top drug office role

8 Dec

•

Summary

A vaccine skeptic was appointed to lead a key FDA drug office.
Senior officials warn the appointment harms the agency's reputation.
Concerns exist about politicization of science-driven drug evaluation.

FDA rocked: Vaccine skeptic takes top drug office role

The Trump administration's appointment of Dr. Tracy Beth Høeg, known for her vaccine skepticism, to lead the FDA's Center for Drug Evaluation and Research has sent shockwaves through the agency. Multiple senior FDA officials expressed grave concerns, likening the appointment to an "atom bomb" that could devastate the agency's reputation and scientific integrity.

Dr. Høeg, an epidemiologist, has previously questioned COVID-19 vaccine recommendations for young men and authored a memo making unsubstantiated claims about child deaths linked to COVID-19 vaccines. Her critics argue she lacks direct experience in drug review and clinical trials, raising fears that the office responsible for drug safety and approval may become politicized.

This leadership change occurs amid recent turmoil in the office, with two prior directors resigning within weeks. Officials worry that pharmaceutical companies may lose confidence in the FDA's stability, potentially leading them to develop new products overseas. Høeg's appointment continues a trend of leadership shifts within the agency this year.